BF-114
Obesity, NAFLD/NASH, MASLD, Hepatocellular Carcinoma (HCC)
PreclinicalActive
Key Facts
Indication
Obesity, NAFLD/NASH, MASLD, Hepatocellular Carcinoma (HCC)
Phase
Preclinical
Status
Active
Company
About Bullfrog AI
Bullfrog AI Holdings, Inc. is a clinical-stage biotechnology company integrating explainable artificial intelligence with drug development to improve precision and success rates. Its core strategy is dual-faceted: developing an internal pipeline of in-licensed oncology and metabolic drug candidates and providing its proprietary AI/ML technology platforms as services to other life sciences organizations. The company's award-winning bfLEAP™ platform, licensed from Johns Hopkins APL, uses graph-based analytics to uncover hidden biological patterns from complex, multimodal data. Bullfrog aims to address the critical industry bottleneck of fragmented data and 'black box' AI models.
View full company profile